22 research outputs found
Eva Machková and Constitution of Modern Czech Drama Education
No full textEva Machková a konstituování české moderní dramatické výchovy
Tato diplomová práce je dokumentem o významné osobnosti v oblasti české dramatické výchovy, Evě Machkové. Zaměřuje se především na činnost Evy Machkové v letech 1960 až 1990, kdy se konstituovala česká moderní dramatická výchova. Práce je rozčleněna na tři časová období, ve kterých je v kontextu vývoje české dramatické výchovy sledován přínos Evy Machkové coby redaktorky, teoretičky, organizátorky dětských národních divadelních přehlídek, dramaturgyně, autorky mnoha odborných publikací atd. Práce se podrobněji věnuje publikační a redaktorské činnosti Evy Machkové; v šedesátých až sedmdesátých letech se jednalo o vydávání odborného periodika Divadelní výchova, v sedmdesátých a osmdesátých letech o nemalý počet odborných publikací z různých oblastí dramatické výchovy.Eva Machkova and Constitution of Modern Czech Drama Education
This thesis is a document about a significant personality within Czech drama education, Eva Machkova. It is particularly concentrated on activities of Eva Machkova during the years from 1960 to 1990, when modern Czech drama education was constituted. The thesis is divided into three time periods and contribution of Eva Machkova as an editress, a theorist, an organizer of national festivals of children´s theatre, a dramaturge, an author of many specialized publications etc. is followed within development of Czech drama education. There is given more detailed information about Eva Machkova´s editing and publishing activities in the thesis, which involves editing of specialized magazine Divadelní výchova (Theatre Education) within 1960´s and 1970´s as well as many other specialized publications from different areas of creative drama in 1970´s and 1980´s
AMČR - archeologický záznam C-9140364A
No full textStav: 3Lokalizace/okolnosti: Při potůčku, který teče mezi Rasoškou a Vlkovem. Podnět: kopání struhy.Souhrn/upřesnění: Roku 1878 vykopal obuvník V. Machek při prohlubování struhy čtyři kamenné nástroje a sice "dva mlaty a dvě dlátka". Jeden z nálezů získal baron Liebig, jeden si ponechal J. Duška, jeden daroval zemskému muzeu v Praze a jeden dostala matka Machkova aby jej užívala jako "klínu hromového"
Surface analysis of doped lanthanide cobalt perovskites by X-ray photoelectron spectroscopy
No full textMultifunctional smart coatings on novel ceramics and glassceramic substrates in the context of the circular economy
No full textNowadays is time of products generated by “smart coatings” that exhibit multiple functionalities. In particular,
the construction industry is reached the point where it is possible to fabricate “smart and sustainable” buildings that
fulfll the requirements of a growing marketplace of products and devices for “smart cities” generation. In addition, if
the buildings are “green”, i.e. in accordance with the today‘s economic model “made to be made again” or so-called
“circular economy” they are very attractive and viable alternative for future businesses and industrial exploring.
In this concept, we report a development sustainable ceramic and glass-ceramic tile substrates made by cheap,
easily accessible and recycled materials that are further functionalized by different “smart coatings” for specifc
applications. Devices that generate and save energy, air and pollution cleaning, with anti-slip and phosphorescence
properties are some examples of the overview that this publication described
P460 Impact of anti-TNFα exposure during pregnancy for maternal inflammatory bowel disease on serologic response to vaccination of exposed children
No full textP734 Anti-TNFa exposure during pregnancy is not associated with increased infection risk in exposed children during the first year of life
No full textA switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn’s disease: an analysis of two propensity score-matched cohorts
No full textOriginator-adalimumab, an established treatment for patients with Crohn’s disease (CD), showed no difference in efficacy or adverse events versus adalimumab biosimilar SB5 (SB5-adalimumab) over 10 weeks (W) of treatment. To understand the long-term effectiveness of SB5-adalimumab in CD, patients switched from originator-adalimumab to SB5-adalimumab were compared with patients remaining on originator-adalimumab over 104 W. Data on patients aged ≥18 years, diagnosed with CD and treated at ISCARE, were collected prospectively from July 2018 to January 2021. Primary outcome: clinical disease activity at W52, measured by Harvey-Bradshaw index (HBI). Secondary outcomes: C-reactive protein (CRP), faecal calprotectin (FC) and adalimumab concentrations at W10, 26, 52 and 104, and treatment persistence. To ensure comparable cohorts, patients were propensity score (PS)-matched for age, gender and disease activity. After matching, 54 patients remained per cohort. At W52, mean (SD) HBI score was 3.2 (2.5) for originator-adalimumab and 4.0 [3.6] for SB5-adalimumab (difference [95% CI] −0.78 [−2.8, 1.3]; n = 18/cohort); no clinically meaningful differences in CRP, FC or drug concentrations were noted. Kaplan–Meier’s estimates (95% CI) of remaining on treatment were originator-adalimumab: 0.870 (0.785–0.965) versus SB5-adalimumab: 0.648 (0.533–0.789) at W52 and significantly lower for SB5-adalimumab versus originator-adalimumab (p n = 20/54 [37%]). These long-term results of CD patients receiving originator-adalimumab or following nonmedical switch to SB5-adalimumab show similar therapeutic effects on clinical disease activity, biological parameters and pharmacokinetic profile in both cohorts from 52 to 104 W. A separation in persistence was observed beyond W26, mainly due to differences in local reactions at the injection site.</p
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial
No full textIMPORTANCE: In phase 2 studies, evolocumab, a fully human monoclonal antibody to PCSK9, reduced LDL-C levels in patients receiving statin therapy. OBJECTIVE: To evaluate the efficacy and tolerability of evolocumab when used in combination with a moderate- vs high-intensity statin. DESIGN, SETTING, AND PATIENTS: Phase 3, 12-week, randomized, double-blind, placebo- and ezetimibe-controlled study conducted between January and December of 2013 in patients with primary hypercholesterolemia and mixed dyslipidemia at 198 sites in 17 countries. INTERVENTIONS: Patients (n = 2067) were randomized to 1 of 24 treatment groups in 2 steps. Patients were initially randomized to a daily, moderate-intensity (atorvastatin [10 mg], simvastatin [40 mg], or rosuvastatin [5 mg]) or high-intensity (atorvastatin [80 mg], rosuvastatin [40 mg]) statin. After a 4-week lipid-stabilization period, patients (n = 1899) were randomized to compare evolocumab (140 mg every 2 weeks or 420 mg monthly) with placebo (every 2 weeks or monthly) or ezetimibe (10 mg or placebo daily; atorvastatin patients only) when added to statin therapies. MAIN OUTCOMES AND MEASURES: Percent change from baseline in low-density lipoprotein cholesterol (LDL-C) level at the mean of weeks 10 and 12 and at week 12. RESULTS: Evolocumab reduced LDL-C levels by 66% (95% CI, 58% to 73%) to 75% (95% CI, 65% to 84%) (every 2 weeks) and by 63% (95% CI, 54% to 71%) to 75% (95% CI, 67% to 83%) (monthly) vs placebo at the mean of weeks 10 and 12 in the moderate- and high-intensity statin-treated groups; the LDL-C reductions at week 12 were comparable. For moderate-intensity statin groups, evolocumab every 2 weeks reduced LDL-C from a baseline mean of 115 to 124 mg/dL to an on-treatment mean of 39 to 49 mg/dL; monthly evolocumab reduced LDL-C from a baseline mean of 123 to 126 mg/dL to an on-treatment mean of 43 to 48 mg/dL. For high-intensity statin groups, evolocumab every 2 weeks reduced LDL-C from a baseline mean of 89 to 94 mg/dL to an on-treatment mean of 35 to 38 mg/dL; monthly evolocumab reduced LDL-C from a baseline mean of 89 to 94 mg/dL to an on-treatment mean of 33 to 35 mg/dL. Adverse events were reported in 36%, 40%, and 39%of evolocumab-, ezetimibe-, and placebo-treated patients, respectively. The most common adverse events in evolocumab-treated patients were back pain, arthralgia, headache, muscle spasms, and pain in extremity (all <2%). CONCLUSIONS AND RELEVANCE: In this 12-week trial conducted among patients with primary hypercholesterolemia and mixed dyslipidemia, evolocumab added to moderate- or high-intensity statin therapy resulted in additional LDL-C lowering. Further studies are needed to evaluate the longer-term clinical outcomes and safety of this approach for LDL-C lowering. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT0176386
